CordenPharma Receives SBTi Approval for Near-Term Science-Based Greenhouse Gas Emission Reduction Targets

Basel, Switzerland – 6 May 2025 > CordenPharma is proud to announce that the Science-Based Targets initiative (SBTi) has officially approved the group’s near-term greenhouse gas (GHG) emission reduction targets. Following a two-year carbon footprint measurement process resulting in a submission of the targets in November 2024, the SBTi’s Target Validation Team has confirmed that the group’s ambition is in conformance with the SBTi Standards and Guidance.

This milestone reflects CordenPharma’s commitment to climate action and underscores its leadership in sustainable pharmaceutical manufacturing.

 CordenPharma’s Approved Near-Term Science-Based Targets:

CordenPharma commits to reduce absolute scope 1 and 2 GHG emissions 55% by 2033 from a 2023 base year.*CordenPharma also commits that 72% of its suppliers by emissions covering purchased goods and services, capital goods, fuel- and energy-related activities, upstream transportation and distribution, and waste generated in operations, will have science-based targets by 2029.*The target boundary includes land-related emissions and removals from bioenergy feedstocks.

The SBTi provides a clear and science-based framework for companies to set emissions reduction targets that support global efforts to limit warming to 1.5°C above pre-industrial levels. For CordenPharma, this validation reinforces its dedication to establishing sustainable practices that support pharma and biotech innovators with the complex modalities they need to improve patient outcomes, while contributing to a healthier planet.

CordenPharma’s Climate Aims Moving Forward:

Transition to 100% renewable electricity across all global facilities. Invest in energy-efficient production processes and facilities to reduce emissions and resource consumption. Collaborate closely with suppliers, customers, and other stakeholders to encourage and implement aligned carbon reduction strategies.

William Cashin, Chief Quality & Compliance Officer at CordenPharma, commented: “Our sustainability teams across all global sites have worked with passion and diligence to develop robust emission reduction targets. Receiving SBTi approval marks a major milestone in our climate journey. With the full support of our shareholders Astorg, we are united in our ambition to lead in climate action and provide greater transparency to our customers, employees, and stakeholders. This validation strengthens our role as a trusted CDMO partner—one that prioritizes environmental responsibility alongside service excellence.”